share_log

Avenue Therapeutics | CORRESP: CORRESP

Avenue Therapeutics | CORRESP:信函

SEC announcement ·  01/30 11:45
Moomoo AI 已提取核心訊息
Avenue Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3. The company aims for the Registration Statement to be declared effective by 5:00 p.m. Eastern time on February 1, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Avenue Therapeutics has authorized Rakesh Gopalan and David Wolpa, attorneys from Troutman Pepper Hamilton Sanders LLP, to modify or withdraw the acceleration request if necessary. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with its legal representatives upon declaration.
Avenue Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3. The company aims for the Registration Statement to be declared effective by 5:00 p.m. Eastern time on February 1, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Avenue Therapeutics has authorized Rakesh Gopalan and David Wolpa, attorneys from Troutman Pepper Hamilton Sanders LLP, to modify or withdraw the acceleration request if necessary. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with its legal representatives upon declaration.
Avenue Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其S-3表格註冊聲明的生效日期。該公司的目標是在美國東部時間2024年2月1日下午 5:00 之前宣佈註冊聲明生效。該請求是根據經修訂的1933年《證券法》第461條提出的。Avenue Therapeutics已授權Troutman Pepper Hamilton Sanders LLP的律師拉克什·戈帕蘭和大衛·沃爾帕在必要時修改或撤回加速請求。該公司已要求美國證券交易委員會在聲明後與其法定代表人口頭確認註冊聲明的有效性。
Avenue Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其S-3表格註冊聲明的生效日期。該公司的目標是在美國東部時間2024年2月1日下午 5:00 之前宣佈註冊聲明生效。該請求是根據經修訂的1933年《證券法》第461條提出的。Avenue Therapeutics已授權Troutman Pepper Hamilton Sanders LLP的律師拉克什·戈帕蘭和大衛·沃爾帕在必要時修改或撤回加速請求。該公司已要求美國證券交易委員會在聲明後與其法定代表人口頭確認註冊聲明的有效性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息